NEWS
[Shanghai, China, 21 May, 2021] SciClone Pharmaceuticals (Holdings) Limited (the “Company” or “SciClone Pharmaceuticals”, together with its subsidiaries, the “Group”, HKEX: 06600) and LinkDoc Technology (“LinkDoc”) announced yesterday that they had entered into a strategic cooperation agreement to establish a long-term, stable and close partnership. SciClone Pharmaceuticals, abounding in medical products of medicine and health and experienced in international service and LinkDoc, with its technologies and channels in tumor big data, real world study, digital healthcare and patient management, will join hands to develop an innovative patient service pattern that combines innovative payment with digital service to comprehensively improve patients’ health through better medical and health services.
Hong Zhao, President and CEO of SciClone Pharmaceuticals,
and Tony Zhang, Founder & CEO of LinkDoc,
sign the strategic cooperation agreement
Cecile Pan, Vice President and CFO of SciClone Pharmaceuticals, Mike Wu，Vice President and Head of MA & CO of SciClone Pharmaceuticals, Jenny Zhu, Senior Director and Head of Business Excellence of SciClone Pharmaceuticals, and Ligang Luo, Co-Founder & COO of LinkDoc, Andy Guo, CBO & President of Digital Business Platform of LinkDoc, Tong Guo, Executive Vice President and Head of Business Solutions of LinkDoc, Ethan Fang, Vice President and Head of Business Development of LinkDoc are at the signing ceremony
In the wake of the fast development of the Internet, big data and AI technologies, the precise and individualized patient management is becoming a reality. Based on SciClone Pharmaceuticals’ commitment to the health industry and LinkDoc’s research and practice in digital management on the full life cycle, the two parties will start with improving patients’ experience, study new medicine channel circulations and delivery patterns and promote their cooperation with SF Pharmaceutical in innovative medicine circulation pattern to improve the accessibility of medicines and the quality of patient service. In April 2021, SciClone Pharmaceuticals and SF Pharmaceutical launched a strategic cooperation to develop a more efficient supply chain service pattern linking healthcare enterprises with C-end patient users and provide professional, safe and traceable end-to-end service.
SciClone Pharmaceuticals and LinkDoc have solid basis for cooperation. Previously, the two parties have put the patient benefit project of “Immunity First” into trial operations. Forming a digital empowerment closed-loop involving “healthcare, medicines and insurance,” the innovative pattern, which combines commercial health insurance service with online and offline digital service, serves patients through the LinkDoc Patient Care Center (PCC) and seeks innovative payment solutions to reduce the financial burden of medical treatment on patients to comprehensively improve patient service. It is expected to benefit tens of thousands of patients.
Hong Zhao
President and Chief Executive Officer of SciClone Pharmaceuticals
According to Mr. Hong Zhao, President and Chief Executive Officer of SciClone Pharmaceuticals, SciClone Pharmaceuticals has been committed to the Chinese market for over 20 years as an international biopharmaceutical company with an integrated platform for product development and commercialization, dedicated to improving patients’ health by providing top-tier healthcare products and services with global standards of care. Devoted to the treatment for critical and special diseases, we use full life cycle management patterns and products to provide precision medical service for people differing in age and health condition. Adhering to the concept of “Center on patients,” SciClone Pharmaceuticals boosts cross-over cooperation in the field of healthcare and has achieved constructive results in digital healthcare and innovative payment. Because of its advanced medical big data and sophisticated technical support service system, we believe that LinkDoc will be our trustworthy partner. Through the cooperation, we will persistently innovate the patient service pattern, enhance the accessibility of high-quality innovative medicines, and help China build up a multi-level medical security system, so as to offer patients better service and promote the innovation of the industry.
Tony Zhang
Founder & CEO of LinkDoc
According to Tony Zhang, Founder & CEO of LinkDoc, LinkDoc, a company focusing on tumor and other critical illness and providing the pharmaceutical industry with precision life science solutions and real-world evidence, is capable of offering commercial service covering the full life cycle and committed to becoming the “accelerator of new medicine launch,” “magnifier of new medicine commercialization” and “improver of mature medicine efficacy.” Meanwhile, cooperating with more than 330 hospitals and clinicians all over China, LinkDoc has established 34 patient care centers in 28 provinces and cities in China by the end of March 2021 and connected offline and online channels via LinkDoc Online Hospital to form the digitally-driven and patient-centered digital health management platform. Besides, by means of full life cycle services such as online diagnostics and treatment, prescription review and circulation, offline medicine delivery and infusion, precise follow-up visit, patient education and rehabilitation management and innovative payment, it offers millions of Chinese patients precise and individualized care and management. We are honored to reach the strategic cooperation with SciClone Pharmaceuticals, the leader in international immunotherapy and special medicines. We do value its professional medicines, experience in international service and brand perception. We believe that we will fit in with and empower each other in terms of capability, resources and platform to benefit more patients with better medicines and services.
#
About SciClone Pharmaceuticals
The Company is a biopharmaceutical company with an integrated platform for product development and commercialization. The Company strategically focuses on some of the largest and fast growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. With its product development and commercialization strength, the Company has established a good track record in terms of balanced and high-quality products on the market in key therapeutic areas and in developing and commercializing portfolios of pipeline products with better potential.
For more information about the Company, please visit www.sciclone.com
#
About LinkDoc Technology
As a data-driven and AI-empowered high-tech healthcare company, LinkDoc Technology is always true to its corporate ethos – “Care Data Care Life”, providing patients and industrial stakeholders (including pharmaceutical manufacturers, medical institutions, insurers, and administrative and regulatory authorities) with one-stop big data solutions, and developing online healthcare platforms for facilitating diagnosis, treatment, and scientific research by doctors, and providing access to satisfactory medications, therapies, and health assurance for patients. LinkDoc has served more than 330 companies and institutions (including 80% of global top 20 life science and pharmaceutical enterprises, all top 10 Chinese pharmaceutical enterprises, and half of Chinese innovative biotechnical companies listed in Hong Kong). Over 200 real-world research projects are being performed by LinkDoc, and more than 3 million Chinese patients have benefited from its services accumulatively.